Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies

Sara Monti, Silvia Balduzzi, Paolo Delvino, Elisa Bellis, Verdiana Serena Quadrelli, Carlomaurizio Montecucco, Sara Monti, Silvia Balduzzi, Paolo Delvino, Elisa Bellis, Verdiana Serena Quadrelli, Carlomaurizio Montecucco

No abstract available

Keywords: antirheumatic agents; arthritis, rheumatoid; biological therapy; spondylitis, ankylosing.

Conflict of interest statement

Competing interests: None declared.

References

    1. Memoli MJ, Athota R, Reed S, et al. . The natural history of influenza infection in the severely immunocompromised vs nonimmunocompromised hosts. Clin Infect Dis 2014;58:214–24.10.1093/cid/cit725
    1. Noreña I, Fernández-Ruiz M, Aguado JM. Viral infections in the biologic therapy era. Expert Rev Anti Infect Ther 2018;16:781–91.10.1080/14787210.2018.1521270
    1. D'Antiga L. Coronaviruses and immunosuppressed patients. The facts during the third epidemic. Liver Transpl 2020. doi:10.1002/lt.25756
    1. Shi Y, Wang Y, Shao C, et al. . COVID-19 infection: the perspectives on immune responses. Cell Death Differ 2020;38210.1038/s41418-020-0530-3
    1. Hui DS, Azhar EI, Kim Y-J, et al. . Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission. Lancet Infect Dis 2018;18:e217–27.10.1016/S1473-3099(18)30127-0

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe